HOME >> BIOLOGY >> NEWS
Abgenix reports positive clinical data with ABX-IL8 in Psoriasis

Improvement Seen with Multiple Parameters of Disease Measurement

FREMONT, Calif., November 30, 1999 - Abgenix, Inc. (Nasdaq: ABGX) today reported top level results of its Phase I/II clinical trial with ABX-IL8, a fully human antibody developed with the company's XenoMouse™ technology. Additional details will be presented at the Psoriasis: from Gene to Clinic meeting in London on December 2,1999. The multi-center, placebo controlled trial involved 45 patients with moderate to severe psoriasis. Abgenix reported that ABX-IL8 was safe and well tolerated at all dose levels tested and that a dose-dependent improvement was seen in multiple measures of disease. These efficacy measures included psoriasis area severity index (PASI), total body surface area (BSA), Physician's Global Assessment (PGA), and plaque photographs. The company also indicated that it plans to initiate a Phase II clinical trial in psoriasis during the first half of 2000. Other inflammatory disease indications including rheumatoid arthritis continue to be evaluated.

PASI analysis is a widely accepted measure of drug response in psoriasis patients. Fifty-eight percent (58%) of the patients who received ABX-IL8 1.0 mg/kg and 3.0 mg/kg, administered once every three weeks for four consecutive doses, achieved a >25% improvement, and 21% of patients achieved a >50% improvement in PASI score. This compared favorably to patients receiving 0.3 mg/kg ABX-IL8 (20% of patients achieved a >25% improvement and 0% a >50% improvement) and to patients receiving placebo (0% of patients with improvement of >25%). BSA and PGA measures and plaque photographs also showed dose dependent improvement.

"The Phase I/II trial of ABX-IL8 was primarily designed to demonstrate safety so it is a nice surprise to see such encouraging results on efficacy parameters," stated R. Scott Greer, president and CEO of Abgenix. "We will be optimizing the dose and regimen of ABX-IL8
'"/>

Contact: Kurt Leutzinger, Abgenix
510-608-6575
Porter Novelli
30-Nov-1999


Page: 1 2 3

Related biology news :

1. Abgenix to become sole owner of Xenomouse fully human antibody technology
2. Abgenix and CuraGen establish large-scale drug development alliance, companies to develop genomics-based human antibody drugs
3. Abgenix initiates phase III clinical trial of graft versus host disease therapy
4. Human Genome Sciences and Abgenix enter a broad collaboration to create fully human antibody therapeutics
5. Abgenix and Chiron enter Xenomouse Technology Collaboration, targets antibody products for autoimmune disease and cancer
6. Abgenix Reports Encouraging Preclinical Results With ABX-EGF In Cancer Research
7. APP reports Abraxane(TM) is active in breast cancer patients who failed taxol or taxotere
8. Scientists question reports of massive ant supercolonies in California and Europe
9. Survey reports fall in stem cell transplants for breast cancer
10. VaxGen reports Phase I clinical trial results of anthrax vaccine candidate
11. Immerge reports PERVs most infectious to human cells not part of germ-line DNA of mini-swine

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Abgenix reports positive clinical data with ABX Psoriasis

(Date:1/22/2015)... man-made form of insulin delivered by nasal spray may ... with mild cognitive impairment and Alzheimer,s disease dementia, according ... Forest Baptist Medical Center. The study,s subjects ... (MCI) or mild to moderate Alzheimer,s dementia (AD). Those ...
(Date:1/22/2015)... Report Issued by Small Cap IR. In 2011, Nilson Report,s ... at merchants on the leading payment cards rose to $135.3 ... and prepaid cards reached 6.54 billion.  Eight million credit card ... in 2012, and credit and debit card fraud resulted in ...
(Date:1/22/2015)... YORK , Jan. 22, 2015   EyeLock, Inc. , ... it has appointed Steve Gerber to the new ... will be responsible for leading development of mobile platforms and ... years of success and innovation in the semiconductor industry to ...
Breaking Biology News(10 mins):Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2
(Date:1/22/2015)... CAMBRIDGE, Mass (PRWEB) January 21, 2015 Cambridge ... Semantic Web technology, today announced that 2014 was a record-breaking ... expanding the capabilities of the Anzo Smart Data Platform and ... discover and utilize insights from diverse data which led to ...
(Date:1/22/2015)... / Rootstown, OH (PRWEB) January 22, 2015 ... platform, announced today that it has received AOAC-PTM Certifications for ... O1O3, O111, O121, and O145; collectively referred to as STEC ... O157, at 1 colony forming unit (cfu) per 325 g ...
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently was invited ... seminar on probiotics in San Diego, CA. , The ... for health care professionals. This year’s pre-conference seminar was held ... health. Dr. Leyer spoke about the emerging topics and science ...
(Date:1/22/2015)... Diagenode, Inc., a leading global ... and complete solutions for epigenetics research, recently launched ... the need for manual processing. The new ChIPettor ... of histones or transcription factors and a semi-automated ...
Breaking Biology Technology:Cambridge Semantics Announces Record Results for 2014 2Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2
Cached News: